Bristol-Myers Squibb Company (FRA:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 94.33B -14.4% |
| Revenue (ttm) | 40.94B +1.3% |
| Net Income | 5.15B |
| EPS | 2.53 |
| Shares Out | n/a |
| PE Ratio | 18.33 |
| Forward PE | 9.54 |
| Dividend | 2.15 (4.65%) |
| Ex-Dividend Date | Jan 2, 2026 |
| Volume | 314 |
| Average Volume | 740 |
| Open | 44.80 |
| Previous Close | 45.67 |
| Day's Range | 44.80 - 46.39 |
| 52-Week Range | 36.65 - 58.50 |
| Beta | n/a |
| RSI | 50.79 |
| Earnings Date | Feb 5, 2026 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
What the Options Market Tells Us About Bristol-Myers Squibb
Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE: BMY) revealed 9 unusual trades. Delving into the details...
San Luis Wealth Advisors LLC Buys 4,185 Shares of Bristol-Myers Squibb Co (BMY)
San Luis Wealth Advisors LLC Buys 4,185 Shares of Bristol-Myers Squibb Co (BMY)
INVESTED ADVISORS Buys 1,638 Shares of Bristol-Myers Squibb Co (BMY)
INVESTED ADVISORS Buys 1,638 Shares of Bristol-Myers Squibb Co (BMY)
BCS Wealth Management Buys 5,221 Shares of Bristol-Myers Squibb Co (BMY)
BCS Wealth Management Buys 5,221 Shares of Bristol-Myers Squibb Co (BMY)
Notable healthcare headlines for the week: J&J, Moderna, Bristol Myers in focus
S&P 500 healthcare weekly update: top gainers/losers and key news on J&J earnings, GSK-RAPT deal, AI lung cancer pact, and UNH rebates—Read now.
Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)
Goldman Sachs Strategic Factor Allocation Fund Buys 34,509 Shares of Bristol-Myers Squibb Co (BMY)
Goldman Sachs Strategic Factor Allocation Fund Buys 34,509 Shares of Bristol-Myers Squibb Co (BMY)
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
VICUS CAPITAL Buys 4,387 Shares of Bristol-Myers Squibb Co (BMY)
VICUS CAPITAL Buys 4,387 Shares of Bristol-Myers Squibb Co (BMY)
Paragon Capital Management Ltd Buys 4,129 Shares of Bristol-Myers Squibb Co (BMY)
Paragon Capital Management Ltd Buys 4,129 Shares of Bristol-Myers Squibb Co (BMY)
True North Advisors, LLC Sells 12,530 Shares of Bristol-Myers Squibb Co (BMY)
True North Advisors, LLC Sells 12,530 Shares of Bristol-Myers Squibb Co (BMY)
RIDGECREST WEALTH PARTNERS, LLC Sells 8,115 Shares of Bristol-Myers Squibb Co (BMY)
RIDGECREST WEALTH PARTNERS, LLC Sells 8,115 Shares of Bristol-Myers Squibb Co (BMY)
Triad Wealth Partners, LLC Buys 6,270 Shares of Bristol-Myers Squibb Co (BMY)
Triad Wealth Partners, LLC Buys 6,270 Shares of Bristol-Myers Squibb Co (BMY)
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY). San Diego-based Janux will receive ...
Ledyard National Bank Sells 351 Shares of Bristol-Myers Squibb Co (BMY)
Ledyard National Bank Sells 351 Shares of Bristol-Myers Squibb Co (BMY)
Newman Dignan & Sheerar, Inc. Buys 393 Shares of Bristol-Myers Squibb Co (BMY)
Newman Dignan & Sheerar, Inc. Buys 393 Shares of Bristol-Myers Squibb Co (BMY)
CLIFTONLARSONALLEN WEALTH ADVISORS, LLC Buys 502 Shares of Bristol-Myers Squibb Co (BMY)
CLIFTONLARSONALLEN WEALTH ADVISORS, LLC Buys 502 Shares of Bristol-Myers Squibb Co (BMY)
Demars Financial Group, LLC Buys 1,207 Shares of Bristol-Myers Squibb Co (BMY)
Demars Financial Group, LLC Buys 1,207 Shares of Bristol-Myers Squibb Co (BMY)
FINANCIAL CONSULATE, INC Sells 148 Shares of Bristol-Myers Squibb Co (BMY)
FINANCIAL CONSULATE, INC Sells 148 Shares of Bristol-Myers Squibb Co (BMY)
Janux Enters Collaboration And Exclusive Worldwide License Agreement With Bristol Myers Squibb
(RTTNews) - Janux Therapeutics Inc. (JANX) has announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to advance a novel therapeutic candidate for solid tumors.
Janux Therapeutics (JANX) Surges on Bristol Myers Squibb Collaboration
Janux Therapeutics (JANX) Surges on Bristol Myers Squibb Collaboration
Bristol Myers (BMY) Partners with Janux Therapeutics on Cancer Treatment
Bristol Myers (BMY) Partners with Janux Therapeutics on Cancer Treatment
Bristol Myers inks licensing deal with Janux for cancer therapy
Janux Therapeutics (JANX) stock jumps as the company inks a licensing deal with Bristol Myers (BMY) to develop a cancer candidate. Read more here.
Independence Bank of Kentucky Sells 349 Shares of Bristol-Myers Squibb Co (BMY)
Independence Bank of Kentucky Sells 349 Shares of Bristol-Myers Squibb Co (BMY)